ArticleThe American journal of case reports2025
Leukemoid Reactions in Pancreatic Cancer: A Case Series.
Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND This article presents a rare case of pancreatic cancer complicated by a leukemoid reaction, alongside 4 similar cases treated at our hospital between 2016 and 2024. Leukemoid reactions are uncommon paraneoplastic manifestations, and their optimal management remains undefined. Herein, we systematically analyze the clinical characteristics and potential molecular mechanisms involved in the development and progression of tumor-associated leukemoid reactions, and summarize our diagnostic and therapeutic approaches. CASE REPORT We reviewed the records of 5 patients at our hospital who had malignancies complicated by leukemoid reactions. Medical histories, laboratory tests, imaging findings, bone marrow biopsy results, and treatment details were collected and analyzed. We explored the pathogenesis, diagnostic strategies, and treatment modalities for leukemoid reactions. A 52-year-old man with advanced pancreatic adenocarcinoma and a KRAS p.G12D mutation, developed extreme leukocytosis (96.22×10⁹ white blood cells/L) in the context of hepatic metastases. Despite broad-spectrum antimicrobial coverage, cytoreductive therapies, and supportive measures (bilirubin adsorption and plasma exchange, continuous veno-venous hemofiltration), his condition rapidly deteriorated, culminating in multi-organ failure. The 4 additional patients - 1 each with metastatic breast cancer, colon cancer, cholangiocarcinoma, and recurrent pancreatic cancer - exhibited similarly aggressive courses, with only transient stabilization observed in the breast cancer case. CONCLUSIONS Patients with malignancies complicated by leukemoid reaction generally have a poor prognosis. Clinicians should be alert to markedly elevated white blood cell counts, promptly investigate underlying causes, and initiate individualized treatments. Future research should focus on the molecular mechanisms driving the development and progression of leukemoid reactions and therapeutic interventions to enhance patient survival and clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.